2-Fluorodeschloroketamine

2-Fluorodeschloroketamine (2-FDCK, also written 2F-DCK or fluoroketamine) is a synthetic dissociative anesthetic of the arylcyclohexylamine class, structurally related to ketamine and deschloroketamine (DCK). It emerged on the research chemical market in the mid-2010s as a legal alternative to ketamine, and rapidly became one of the most popular dissociative RCs owing to its profile of effects that community members describe as sitting between ketamine and DCK — somewhat longer-lasting and more "mind-opening" than ketamine, with a cleaner headspace than DCK.

Like all arylcyclohexylamines, 2-FDCK acts primarily as an NMDA receptor antagonist, producing dose-dependent dissociative effects ranging from mild perceptual alterations at threshold doses through pronounced dissociation, visual distortions, time distortion, and ego dissolution (the "k-hole" equivalent) at high doses. At subanesthetic doses it produces euphoria, music enhancement, and a characteristic dissociative "headspace" that users frequently describe as introspective and thought-provoking. The fluorine substitution at the 2-position of the cyclohexyl ring alters metabolism relative to ketamine, producing a longer duration of action — typically 90 minutes to 3 hours at recreational doses versus 45–90 minutes for ketamine.

Community experience emphasizes that 2-FDCK is substantially more potent by weight than ketamine, with active doses beginning around 10–20 mg insufflated. Compulsive redosing and frequent use carry the same bladder toxicity risks established for ketamine, and this risk is considered a primary harm reduction concern. The substance has been used in social settings (concerts, festivals) at low doses for music enhancement, and in solo introspective settings at higher doses for exploratory experiences.